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Abstract Percutaneous coronary intervention (PCI)
based on fractional flow reserve (FFRcath) measurement
during invasive coronary angiography (CAG) results in
improved patient outcome and reduced healthcare costs.
FFR can now be computed non-invasively from standard
coronary CT angiography (cCTA) scans (FFRCT). The
purpose of this study is to determine the potential impact of
non-invasive FFRCT on costs and clinical outcomes of
patients with suspected coronary artery disease in Japan.
Clinical data from 254 patients in the HeartFlowNXT trial,
costs of goods and services in Japan, and clinical outcome
data from the literature were used to estimate the costs and
outcomes of 4 clinical pathways: (1) CAG-visual guided
PCI, (2) CAG-FFRcath guided PCI, (3) cCTA followed by
CAG-visual guided PCI, (4) cCTA-FFRCT guided PCI. The
CAG-visual strategy demonstrated the highest projected
cost ($10,360) and highest projected 1-year death/myo-
cardial infarction rate (2.4 %). An assumed price for
FFRCT of US $2,000 produced equivalent clinical out-
comes (death/MI rate: 1.9 %) and healthcare costs ($7,222)
for the cCTA-FFRCT strategy and the CAG-FFRcath guided
PCI strategy. Use of the cCTA-FFRCT strategy to select
patients for PCI would result in 32 % lower costs and 19 %
fewer cardiac events at 1 year compared to the most
commonly used CAG-visual strategy. Use of cCTA-FFRCT
to select patients for CAG and PCI may reduce costs and
improve clinical outcome in patients with suspected coro-
nary artery disease in Japan.
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Introduction
Prior studies have shown clinical and economic benefits
from assessing and utilizing invasive fractional flow
reserve (FFRcath) measurements to guide percutaneous
coronary intervention (PCI). In the randomized controlled
fractional flow reserve versus angiography for multivessel
evaluation (FAME) study including 1,005 patients, it was
demonstrated that deferring PCI in vessels not associated
with myocardial ischemia based on FFRcath resulted in
improved clinical outcomes and lower costs [1, 2]. Fur-
thermore, the FAME II study involving 888 patients
demonstrated that PCI in vessels associated with myocar-
dial ischemia based on FFRcath significantly reduced urgent
revascularization when compared to medical therapy alone
[3]. In all studies published to date, invasive FFR has been
assessed during angiography (FFRcath). While FFRcath is
widely recommended and offers clinical and economic
benefits, it is not yet widely used due to inconvenience and
costs [4].
A new technology based on standard coronary computed
tomographic angiography (cCTA) allows FFR to be esti-
mated non-invasively (FFRCT) before sending a patient to
angiography. Three prospective, multicenter, validation
studies have been performed (DISCOVER-FLOW—diag-
nosis of ischemia-causing stenosis obtained via non-inva-
sive fractional flow reserve [5]; DeFACTO—determination
of fractional flow reserve by anatomic computed tomo-
graphic angiography [6]; and HeartFlowNXT—HeartFlow
analysis of coronary blood flow using CT angiography:
NeXT steps [7] to determine the diagnostic accuracy of
FFRCT using FFRcath as the reference standard. Good
concordance between FFRCT and FFRcath was found with
high diagnostic accuracy of FFRCT for the detection or
exclusion of hemodynamically significant stenosis using
FFR B0.80 as the reference standard.
An analysis of potential costs and consequences of uti-
lizing FFRCT to guide clinical decision-making in the
United States has suggested the possibility of meaningful
cost savings and clinical benefits [8]. In the present paper,
we report a similar analysis, using data from the most
recently published trial, HeartFlowNXT [7], as well as
Japanese procedure and device cost information. The pri-
mary objective of this analysis is to determine the potential
magnitude of cost savings and clinical benefit which could
be expected in Japan through utilization of FFRCT.
Methods
We used data from 254 patients enrolled in the Heart-
FlowNXT trial [7]. All patients had known or suspected
stable coronary artery disease (CAD) and were scheduled
for coronary angiography (CAG). Each patient in the trial
was evaluated with cCTA, FFRCT, clinically-indicated
CAG and FFRcath. Calculation of FFRCT from standard
acquired cCTA images and evaluation of FFRcath were
performed independently at core laboratories [7]. The study
results demonstrated that FFRCT provided high per-patient
diagnostic accuracy (81 %) for the detection of hemody-
namically significant CAD with a sensitivity of 86 %
(95 % CI 77–92 %) and specificity of 79 % (95 CI
72–84 %) using FFRcath as the reference standard. FFRCT
also provided excellent discrimination of patients with and
without lesion-specific ischemia with an area under the
receiver-operating characteristics curve of 0.90 (95 % CI
0.87–0.94 %) [7]. Using patient-specific data from this
study, we modeled four hypothetical diagnostic/treatment
pathways for patients with known or suspected CAD who
are scheduled for coronary angiography (Fig. 1):
1. Pathway 1: CAG-visual: all patients undergo coronary
angiography as scheduled. Those with C50 % stenosis
by visual assessment of angiographic images undergo
PCI.
2. Pathway 2: CAG-FFRcath: all patients undergo angi-
ography as scheduled. Those patients with C50 %
stenosis undergo FFRcath and only those with FFRcath
B0.80 undergo PCI.
3. Pathway 3: cCTA-CAG: all patients undergo cCTA.
Only those with C50 % cCTA stenosis undergo CAG.
Those with C50 % stenosis by visual assessment of the
angiogram undergo PCI.
4. Pathway 4: cCTA-FFRCT-CAG: all patients undergo
cCTA. Those with C50 % stenosis by cCTA undergo
FFRCT. Only those with FFRCT B0.80 undergo CAG
and PCI is performed after visual angiographic confir-
mation of the stenosis.
For each pathway, we estimated the costs in Japan in
accord with the Japanese Ministry of Health, Labour and
Welfare (MHLW) medical insurance medical expense
database [9]. We considered cost data from the detailed
economic analysis in the 2 years follow-up report of the
FAME study [1] and applied the conversion rate of 93.42
Yen/Dollar. The peri-procedural costs utilized in this study
are shown in Table 1. While the actual cost of FFRCT
analysis has not yet been determined, for the purposes of
this analysis, we sought the cost of FFRCT which produced
equivalence between the costs of Pathway 2 and Pathway
4. This was calculated to be $2,000, which is comparable to
the FFRcath disposable costs ? CAG procedure fee as
reimbursed by the MHLW medical insurance. The analysis
of each pathway involved totaling the costs for each test
and procedure described for all patients in that pathway and
dividing by the total number of patients (254) giving the
average cost per patient.
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We estimated future event rates for appropriately and
inappropriately treated patients using the FFR cutoff value
of \0.80 drawing on data from the deferral versus perfor-
mance of PTCA in patients without documented ischemia
(DEFER) [10], FAME [11, 12] and providing regional
observations to study predictors of events in the coronary
tree (PROSPECT) [13] studies. We considered a coronary
lesion to be significant by visual assessment of the CAG or
cCTA if lumen stenosis was C50 % and defined functional
significance of a lesion as either an FFRcath or FFRCT of
B0.80. Accordingly, we used the following assumptions to
estimate the combined 1 year death/MI rate for: (a) PCI in
patients with FFRcath B0.80: 3 %; (b) PCI in patients with
FFRcath [0.80: 3 %; (c) medical therapy in patients with
Fig. 1 Outline of 4 hypothetical diagnostic/treatment strategies applied to the 254 patient population from the HeartFlowNXT clinical trial
Table 1 Procedural costs used
in the analysis
Costs per procedure Procedure fee Device cost Hospital stay Total costs
Per night Avg nights Total
Angio $420 $60 $1,500 1.4 $2,100 $2,580
PCI-1 vessel $2,550 $5,789 $1,500 2.0 $3,000 $11,339
PCI-2 vessel $2,550 $9,802 $1,500 2.0 $3,000 $15,352
PCI-3 vessel $2,550 $13,815 $1,500 2.0 $3,000 $19,365
cCTA $400 – – 0.0 – $400
FFR $42 $1,800 – 0.0 – $1,842
Price FFRct – $2,000 – 0.0 – $2,000
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FFRcath [0.80: 1 %; (d) medical therapy in patients with
FFRcath B0.80: 5 %; (e) invasive measurement of FFRcath:
0.4 % [7, 14].
Results
A total of 254 patients from the international, multicenter
HeartFlowNXT trial had complete information and were
included in the analysis. Fifty-seven patients (22 %) in the
study were from Japanese clinical sites. Patient character-
istics are shown in Table 2. One-third of the patients (80/
254) had ischemia-causing stenoses with FFR B0.80 and
21 % of the 484 vessels in which invasive FFR was mea-
sured had FFRcath B0.80.
Utilization and costs
In this analysis, we modeled the expected cost to treat each
patient. The overall cost for each patient is dependent on
the test(s) utilized in a given pathway, the lesion mea-
surements for each test, the order in which tests are per-
formed and the treatment performed in accord with the test
results. As discussed above, in this analysis we included
four hypothetical clinical pathways. The average per-
patient cost, for each clinical pathway is shown on Table 3.
In the most commonly used clinical strategy, CAG
visual (Pathway 1), all patients would undergo CAG, 62 %
would undergo PCI and 80 vessels per 100 patients would
be treated based on visual assessment of the angiogram
with an average cost of $10,360 per patient. In Pathway 2,
FFRcath was used to select patients for PCI and only 29 %
of patients would undergo PCI with 37 vessels per 100
patients requiring PCI, assuming strict adherence to the
recommended threshold of FFRcath B0.80. This 54 %
reduction in PCI would result in a potential average cost of
$7,222 per patient corresponding to a 30 % savings per
patient when compared to Pathway 1. In Pathway 3,
cCCTA was used to select patients for CAG reducing the
number of angiograms by 25 % and the number of patients
undergoing PCI by 13 % compared to Pathway 1 (CAG
visual). PCI was guided by visual CAG and the number of
vessels treated was reduced by only 10 % with average
cost savings of 12 % relative to Pathway 1. In Pathway 4,
the strategy of initial cCCTA with FFRCT in patients with
C50 % stenosis and CAG only in those with FFRCT B0.80
reduced the number of angiograms by 62 % and number of
patients undergoing PCI by 47 %. Only 48 vessels per 100
patients needed PCI with an average cost per patient of
$7,222, a 30 % cost savings per patient compared to
Pathway 1.
Clinical events
The estimated one-year rate of death or MI for the CAG
visual-guided strategy (Pathway 1) was 2.4 % (Table 3).
Use of cCTA to select patients for CAG (Pathway 3)
reduced the death/MI rate to 2.2 % due to the reduction in
number of CAG. The use of FFRcath or FFRCT to guide PCI
treatment (Pathways 2 and 4) resulted in the greatest
reduction (21 %) in death/MI rate to 1.9 % compared to
visual angiography-guided treatment. The combined
effects of cost and clinical event rate are shown in Fig. 2.
Discussion
Three prospective, multicenter clinical trials, comprising
609 patients and 1,050 vessels have evaluated the diag-
nostic accuracy of FFRCT using FFRcath as the reference
standard [5–7]. Each study has shown FFRCT to have high
diagnostic accuracy for the diagnosis of lesion-specific
Table 2 Characteristics of study population (n = 254)
Age ± SD (range) 64 ± 10 years (32–84 years)
Men:women (%) 162:92 (64:36 %)
Asian:Caucasian (%) 86:163 (34:64 %)
Hyperlipidemia (%) 200 (79 %)
Hypertension (%) 174 (69 %)
Diabetes (%) 58 (23 %)
Current smoking (%) 46 (18 %)
Prior myocardial infarction (%) 5 (2 %)
Angina within past month (%) 197 (78 %)
Table 3 Peri-procedural costs









No. of patients undergoing CAG (per 100
pts)
100 100 75 38
No. of patients undergoing PCI (per 100
pts)
62 29 54 33
Vessels treated by PCI (per 100 pts) 80 37 72 48
Costs per patient $10,360 $7,222 $9,128 $7,222
1 year event rate 2.4 % 1.9 % 2.2 % 1.9 %
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ischemia using FFRcath as the reference standard with
significant improvement in the ability to discriminate
patients with and without ischemia when compared to
cCTA [5–7] and CAG [7]. The use of invasive FFRcath to
identify lesion-specific ischemia and guide coronary
intervention is now well-established and has been shown to
not only improve patient outcome but also reduce costs [1].
It has been suggested that non-invasive FFRCT may be
poised to assume the role of gatekeeper to the interven-
tional catheterization laboratory, especially for intermedi-
ate stenosis [15], and a previously modeled analysis based
on US data has suggested that the use of FFRCT may
improve patient outcomes while reducing healthcare costs
[8].
In this study we based our analysis on the most recently
published experience with FFRCT which incorporates the
latest refinements in software technology with automated
image processing and improved physiologic modeling of
coronary flow parameters [7]. The results show that the
diagnostic performance of non-invasive FFRCT compares
favorably to invasive FFRcath and can discriminate
ischemia-causing stenoses from non-functional stenoses.
According to European Society of Cardiology [16] and
American Heart Association [17] practice guidelines,
FFRcath is the gold standard for assessing the hemody-
namic significance of coronary lesions and for interven-
tional clinical decision-making; however, FFRcath is not
practical in many cases for reasons of safety and time.
FFRCT has potential value in selecting patients for CAG
and interventional treatment with the potential of achiev-
ing significant reduction in costs and improving outcomes
compared to visual angiography-guided treatment. As
indicated by the model in this study, the utilization of
FFRCT in Japan may result in fewer diagnostic catheter-
izations, fewer inappropriate PCI treatments, improved
patient outcomes, and a 30 % reduction in average cost
per patient relative to standard care (Pathway 1) if fully
implemented.
In addition to advancing patient care, utilizing FFRCT
technology in Japan may provide significant cost savings
for the overall Japanese Healthcare System by safely
deferring unnecessary CAG and identifying patients who
would benefit from PCI. In 2011 it is estimated that
504,476 coronary angiographies and 181,991 non-emer-
gent PCIs were performed in Japan [18]. If our analysis
can be extrapolated to the larger population, the utili-
zation of FFRCT might decrease coronary angiographies
by as much as *60 % and PCI procedures by *40 %.
Based on the results in this study, we estimate that
widespread implementation of FFRCT in Japan has the
potential to result in considerable cost savings to the
Japanese Healthcare System while improving the clinical
outcome for patients.
Study limitations
This study has several important limitations. First, this
study is a simulation of possible costs and outcomes rather
than documentation of costs incurred and outcomes expe-
rienced utilizing FFRCT in actual clinical practice. While
direct assessment of cost-efficacy is not yet available for
FFRCT or other non-invasive testing modalities in stable
CAD, the source data for this study represents the largest
clinical experience of any non-invasive testing modality
using FFRcath as the reference standard. FFRCT has close
direct correlation to measured FFR, which has well-docu-
mented outcome and cost data in more than 1,005 patients
[11], but independent confirmation with actual outcome
data utilizing FFRCT for clinical decision making is nee-
ded. The extent to which patients analyzed in this report
may not precisely reflect the spectrum of patients under-
going CAG in Japan may limit the ability to extrapolate
directly to expected outcomes in Japan. A prospective
longitudinal study evaluating clinical outcomes, resource
utilization and quality of life of FFRCT-guided evaluation
Fig. 2 Combined per-patient
cost and projected 1 year event
rate (death/MI) for 4 clinical
pathways modeled in this study.
FFRcath and FFRCT guided
clinical pathways demonstrated
the lowest cost and clinical
event rate compared to visual-
guided treatment strategies
42 T. Kimura et al.
123
and treatment of patients with suspected CAD is currently
underway (PLATFORM trial, clinical trials.gov
NCT01943903). Second, this study did not include patients
with acute coronary ischemia, patients with prior PCI or
CABG, and patients who are not suitable candidates for
cCTA. Thus, the usefulness of FFRCT in this broader
population of patients with CAD is unknown. Third, costs
related to clinical adverse events during follow-up were not
considered; however, the FFRCT guided pathway had the
lowest event rate during follow-up. Fourth, FFRCT is not
yet widely available and market pricing for this test has not
yet been determined. This analysis uses an FFRCT price of
$2,000, the price at which the costs of Pathways 2 and 4
were equivalent. The resulting average total cost of treating
a patient in Pathway 4 (cCTA-FFRCT-CAG) is $7,222. If
the price of FFRCT is modeled as $1,500, the average cost
of treating a patient in this pathway decreases to $6,848, a
34 % savings compared to standard care (Pathway 1). If the
price of FFRCT is modeled as $2,500, the average cost for a
patient in this pathway is $7,596, a 27 % reduction com-
pared to standard care (Pathway 1). Finally, this analysis
does not consider the possibility of only partial or limited
adoption of the FFRCT decision pathway, which inherently
would limit the potential cost savings of this approach. For
example, the decision to send a patient to CAG is made by
comprehensive evaluation of the patient’s symptoms and
physical findings, risk profile, and results of other non-inva-
sive tests for myocardial ischemia and may cause the physi-
cian to override the results of the FFRCT. Similarly, physicians
in Pathway 2 may choose to—not measure FFR in the cath lab
or may override the results of FFRcath thus reducing the
potential economic and outcome benefit. Thus, actual savings
achieved may be limited by physicians’ adherence to the
clinical decision making pathway. Further evaluations
including prospective outcome studies are underway to better
understand and quantify the potential clinical and economic
improvements identified in this simulation.
Conclusion
Analysis of data from the HeartFlowNXT trial and using
Japanese costs of goods and services suggest that utiliza-
tion of non-invasive FFRCT for clinical decision making
could improve clinical outcomes and decrease costs by
more accurately identifying patients for CAG and PCI.
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